10/10 Many thanks to all contributors from @TheHassanLab, @InstitutCerveau, our collaborators from Olivier Raineteau lab and funders (ANR NeoRepair & ANR NeoReGen, @France_SEP, BDL Capital Management)

9/10 These findings support the repurposing of leucovorin and dyclonine for clinical trials targeting myelin disorders, offering potential therapeutic avenues for preterm brain injury and Multiple Sclerosis

8/10 In an adult MS model of focal de/remyelination, they improve lesion repair by promoting OPC differentiation while preserving the OPC pool. They also shift microglia from a pro-inflammatory to a pro-regenerative profile and enhance myelin debris clearance

7/10 In a neonatal chronic hypoxia mouse model mimicking early preterm brain injury, both compounds promote neural progenitor cell proliferation and oligodendroglial fate acquisition, with leucovorin further enhancing differentiation

6/10 From the top 11 compounds, through in vitro neural and oligodendrocyte progenitor cell (OPC) cultures, ex vivo cerebellar explants, and in vivo mouse models of PBI and MS, we identify FDA-approved leucovorin and dyclonine as promising candidates

5/10 OligoScore allowed us to rate and rank the pro-oligodendrogenic compounds based in their target genes being curated, selecting those impacting several processes, thus having a large pro-oligodendrogenic activities

4/10 We then created the OligoScore resource by curating genes for which loss- & gain-of-function studies have shown their requirement in the main processes of oligodendrogenesis (categorized in specification, proliferation, …, & (re)myelination)

3/10 We then use SPIED as a pharmacogenomic strategy to identify compounds promoting the genes of the oligodendroglial transcriptional signature obtaining 500 candidate oligodendrogenic small molecules

2/10 We first generated transcriptional signature of oligodendroglia (oligodendrocytes and their precursor cells, OPCs), by transcriptomic comparison with other brain cells, also integrating their signature at different stages of development

1/10 Delighted that our study using pharmacogenomics to find compounds promoting oligodendrogenesis and repair in myelin pathologies is now published in Nat Communs, after 7 years of work! https://t.co/kaf1MTlukO (DOI: 10.1038/s41467-024-54003-9)

We invite you to become member and register for free on the website https://t.co/ugG5TG3bRC, involving colleagues who may be interested in this initiative

Our latest paper out by @merbengochea @TheHassanLab about the numerical cognitive abilities of flies and the first evidence for the neurons required for this capacity in the visual system

French glial cell happy hour in Berlin ,🙃

Et si la maladie d’#Alzheimer imprimait sa marque chez l’embryon ? Des scientifiques de l’@InstitutCerveau (@inserm), montrent que la protéine précurseur de l’amyloïde (APP) possède un rôle biologique spécifique lors du neurodéveloppement. https://t.co/0MSCizBaO6

@ShabaniDania @TheHassanLab @InstitutCerveau @ParisBrainInst paper on how the APP protein-famous for its role in Alzheimer’s disease- is actually a regulator of the tempo of human cortical development is now out in @ScienceAdvances https://t.co/BjRgxbrzdx

June 20th in Paris: 'The Times of Embryonic Development’ A symposium at Collège de France @cdf1530. Open, no registration, super speakers 👇🏼@PourquieO @DesplanLab @briscoejames @EbisuyaMiki @VanderhaeghenP2 @maitrejl @Anissakempf @gregorscience @the_Node @LecuitLab

https://t.co/RwWtmAukbk European Parliament is about to discuss a complete ban for animal research. This is real and will be catastrophic for progress in the fight against many diseases. Please support @EU_Brain pledge:

My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:

I am delighted to tell you that our paper on Tensin3 is now available as html version in eLife https://t.co/PpllEoKOpK, with a great layout and lots of shared data files. Thanks a lot to all the people involved! particularly to @EmericMerour and @TheHassanLab at @ParisBrainInst

As promised @GordonConf#Myelin here is the revised version after Review Commons peer-review of our Tns3 paper, that has been submitted now to eLife. I hope you will appreciate the improvements.  https://t.co/Tn4P61gkZO